1. Home
  2. SCD vs CABA Comparison

SCD vs CABA Comparison

Compare SCD & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LMP Capital and Income Fund Inc.

SCD

LMP Capital and Income Fund Inc.

N/A

Current Price

$14.67

Market Cap

357.8M

Sector

Finance

ML Signal

N/A

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

N/A

Current Price

$1.08

Market Cap

339.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCD
CABA
Founded
2003
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
357.8M
339.1M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SCD
CABA
Price
$14.67
$1.08
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $11.75
AVG Volume (30 Days)
59.7K
★ 4.3M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 9.63%
N/A
EPS Growth
N/A
★ 10.26
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.79
$0.98
52 Week High
$16.18
$4.23

Technical Indicators

Market Signals
Indicator
SCD
CABA
Relative Strength Index (RSI) 40.12 30.99
Support Level N/A N/A
Resistance Level $15.53 $1.59
Average True Range (ATR) 0.33 0.14
MACD -0.03 -0.01
Stochastic Oscillator 0.00 15.42

Price Performance

Historical Comparison
SCD
CABA

About SCD LMP Capital and Income Fund Inc.

Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: